Cited by 1,217Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 159 of the 161 references it cites were found in a registry or an index.

Alzheimer’s disease: Clinical trials and drug development

Mangialasche, Francesca, Solomon, Alina, Winblad, Bengt, Mecocci, Patrizia, Kivipelto, Miia·2010·The Lancet Neurology

DOI 10.1016/s1474-4422(10)70119-8

Open this paper in CoChat — free account

Abstract

Alzheimer's disease is the most common cause of dementia in elderly people. Research into Alzheimer's disease therapy has been at least partly successful in terms of developing symptomatic treatments, but has also had several failures in terms of developing disease-modifying therapies. These successes and failures have led to debate about the potential deficiencies in our understanding of the pathogenesis of Alzheimer's disease and potential pitfalls in diagnosis, choice of therapeutic targets, development of drug candidates, and design of clinical trials. Many clinical and experimental studies are ongoing, but we need to acknowledge that a single cure for Alzheimer's disease is unlikely to be found and that the approach to drug development for this disorder needs to be reconsidered. Preclinical research is constantly providing us with new information on pieces of the complex Alzheimer's disease puzzle, and an analysis of this information might reveal patterns of pharmacological interactions instead of single potential drug targets. Several promising randomised controlled trials are ongoing, and the increased collaboration between pharmaceutical companies, basic researchers, and clinical researchers has the potential to bring us closer to developing an optimum pharmaceutical approach for the treatment of Alzheimer's disease.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(10)70119-8

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Alzheimer’s disease
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560

Show all 161 references

Research works printed but not linked: 3

Solomon, 2010, A new target for Alzheimer's disease immunotherapy. 11th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2010, Geneva, Switzerland, Neurobiol Aging, 31, S29
Lenz R, Berry SM, Pritchett YL, et al. Novel investigation of a neuronal nicotinic receptor partial agonist in the treatment of Alzheimer's disease. 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; Geneva, Switzerland; March 24–27, 2010. P100.
Eriksdotter, 2010, Therapy of Alzheimer's disease with NGF. 11th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2010, Geneva, Switzerland, Neurobiol Aging, 31, S9

Sorted by citations

Items 301–400 of 1,000

Functionalization with TAT-Peptide Enhances Blood-Brain Barrier Crossing In vitro of Nanoliposomes Carrying a Curcumin-Derivative to Bind Amyloid-Β Peptide
Sancini, G. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000171 · Cited by 53
The clinical feasibility of deep learning-based classification of amyloid PET images in visually equivocal cases
Son, H. J., Oh, J. S., Oh, M., Kim, S. J., Lee, J., Roh, J. H., & Kim, J. S. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04595-y · Cited by 52
New Hybrids of 4-Amino-2,3-polymethylene-quinoline and p-Tolylsulfonamide as Dual Inhibitors of Acetyl- and Butyrylcholinesterase and Potential Multifunctional Agents for Alzheimer’s Disease Treatment
Makhaeva, G. F., Kovaleva, N. V., Boltneva, N. P., Lushchekina, S. V., Astakhova, T. Y., Rudakova, E. V., Proshin, A. N., Serkov, I. V., Radchenko, E. V., Palyulin, V. A., et al. (2020) · Molecules · doi:10.3390/molecules25173915 · Cited by 53
Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer’s disease
Murakami, K. (2014) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2014.940275 · Cited by 53
Multiple Targeting Approaches on Histamine H3 Receptor Antagonists
Khanfar, M. A., Affini, A., Lutsenko, K., Nikolic, K. M., Butini, S., & Stark, H. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00201 · Cited by 53
Machine Learning Predictive Models Can Improve Efficacy of Clinical Trials for Alzheimer’s Disease
Ezzati, A., Initiative, A. D. N., & Lipton, R. B. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190822 · Cited by 53
Structure-based design of novel donepezil-like hybrids for a multi-target approach to the therapy of Alzheimer's disease
Brunetti, L., Leuci, R., Carrieri, A., Catto, M., Occhineri, S., Vinci, G., Gambacorta, L., Baltrukevich, H., Chaves, S., Laghezza, A., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114358 · Cited by 52
Computer-Aided Structure-Based Design of Multitarget Leads for Alzheimer’s Disease
Domínguez, J. L., Fernández‐Nieto, F., Castro, M., Catto, M., Paleo, M. R., Porto, S., Sardina, F. J., Brea, J. M., Carotti, A., Villaverde, M. C., et al. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500555g · Cited by 53
Beta-amyloid auto-antibodies are reduced in Alzheimer's disease
Qu, B.-X., Gong, Y., Moore, C., Fu, M., German, D. C., Chang, L.-Y., Rosenberg, R., & Diaz-Arrastia, R. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.06.017 · Cited by 47
Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer’s disease models: a systematic review and meta-analysis of preclinical studies
Kong, F., Wu, T., Dai, J., Zhai, Z., Cai, J., Zhu, Z., Xu, Y., & Sun, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205207 · Cited by 54
Mechanisms of Cognitive Impairment in Depression. May Probiotics Help?
Dobielska, M., Bartosik, N. K., Zyzik, K. A., Kowalczyk, E., & Karbownik, M. S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.904426 · Cited by 57
Current Epidemiological Approaches to the Metabolic-Cognitive Syndrome
Panza, F., Solfrizzi, V., Logroscino, G., Maggi, S., Santamato, A., Seripa, D., & Pilotto, A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111496 · Cited by 52
Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases
Katsuno, M., Tanaka, F., & Sobue, G. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301307 · Cited by 52
Management of Alzheimer’s disease—An insight of the enzymatic and other novel potential targets
Islam, B. U., & Tabrez, S. S. M. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.01.076 · Cited by 55
Osthole Stimulated Neural Stem Cells Differentiation into Neurons in an Alzheimer's Disease Cell Model via Upregulation of MicroRNA-9 and Rescued the Functional Impairment of Hippocampal Neurons in APP/PS1 Transgenic Mice
Li, S.-H., Gao, P., Wang, L.-T., Yan, Y.-H., Xia, Y., Song, J., Li, H.-Y., & Yang, J.-X. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00340 · Cited by 46
Preparation of Tetradentate Copper Chelators as Potential Anti‐Alzheimer Agents
Zhang, W., Huang, D., Huang, M., Huang, J., Wang, D., Liu, X., Nguyen, M., Vendier, L., Mazères, S., Robert, A., et al. (2018) · ChemMedChem · doi:10.1002/cmdc.201700734 · Cited by 51
Regular Exercise Enhances Cognitive Function and Intracephalic GLUT Expression in Alzheimer’s Disease Model Mice
Pang, R., Wang, X., Pei, F., Zhang, W.-Z., Shen, J., Gao, X.-Q., & Chang, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190328 · Cited by 45
Development of the First WHO Guidelines for Risk Reduction of Cognitive Decline and Dementia: Lessons Learned and Future Directions
Stephen, R., Barbera, M., Peters, R. K., Ee, N., Zheng, L., Lehtisalo, J., Kulmala, J., Håkansson, K., Chowdhary, N., Dua, T., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.763573 · Cited by 58
Self-citation
A review on traditional Chinese medicine natural products and acupuncture intervention for Alzheimer’s disease based on the neuroinflammatory
Chen, Z., Wang, X., Du, S., Liu, Q., Xu, Z., Guo, Y., & Lin, X. (2024) · Chinese Medicine · doi:10.1186/s13020-024-00900-6 · Cited by 59
The societal costs of dementia in Sweden 2012 – relevance and methodological challenges in valuing informal care
Wimo, A. B., Jönsson, L., Fratiglioni, L., Sandman, P. O., Gustavsson, A., Sköldunger, A., & Johansson, L. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0215-9 · Cited by 54
Fluoxetine attenuates the impairment of spatial learning ability and prevents neuron loss in middle-aged APPswe/PSEN1dE9 double transgenic Alzheimer's disease mice
Ma, J., Gao, Y., Jiang, L. H., Chao, F., Huang, W., Zhou, C., Tang, W. X., Zhang, L., Huang, C., Zhang, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15398 · Cited by 52
Dementias
Sacuiu, S. F. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802973-2.00008-2 · Cited by 57
Gamma rhythm low field magnetic stimulation alleviates neuropathologic changes and rescues memory and cognitive impairments in a mouse model of Alzheimer's disease
Zhen, J., Qian, Y., Weng, X., Su, W., Zhang, J., Cai, L., Dong, L., An, H., Su, R., Wang, J., et al. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.07.002 · Cited by 52
Estrogen-related receptor alpha is involved in Alzheimer's disease-like pathology
Tang, Y., Min, Z., Xiang, X., Liu, L., Ma, Y., Zhu, B., Li, S., Tang, J., Deng, X., Yan, Z., et al. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.04.003 · Cited by 51
Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review
Kochman, U., Sitka, H., Kuźniar, J., Czaja, M., Kozubek, P., Beszłej, J. A., & Leszek, J. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05417-z · Cited by 60
Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease
D’Onofrio, G., Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Paroni, G., Cascavilla, L., Seripa, D., & Pilotto, A. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.645534 · Cited by 52
SCM-198 inhibits microglial overactivation and attenuates Aβ1-40-induced cognitive impairments in rats via JNK and NF-кB pathways
Hong, Z., Shi, X., Zhu, K., Wu, T., & Zhu, Y. Z. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0147-x · Cited by 50
Rice Bran Extract Compensates Mitochondrial Dysfunction in a Cellular Model of Early Alzheimer's Disease
Hagl, S., Grewal, R., Ciobanu, I., Helal, A. M., Khayyal, M. T., Muller, W. E., & Eckert, G. P. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132084 · Cited by 50
Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease
Corbett, A., Williams, G. H., & Ballard, C. G. (2013) · Pharmaceuticals · doi:10.3390/ph6101304 · Cited by 50
Identification of a novel endophytic fungus from Huperzia serrata which produces huperzine A
Shu, S., Zhao, X., Wang, W., Zhang, G., Coșoveanu, A., Ahn, Y., & Wang, M. (2014) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-014-1737-6 · Cited by 50
Looking for a generic inhibitor of amyloid-like fibril formation among flavone derivatives
Šneideris, T., Baranauskienė, L., Cannon, J. G., Rutkienė, R., Meškys, R., & Smirnovas, V. (2015) · PeerJ · doi:10.7717/peerj.1271 · Cited by 50
Application of Nanodiagnostics and Nanotherapy to CNS Diseases
Zhang, W., Wang, W., Yu, D. X., Xiao, Z., & He, Z. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0163 · Cited by 51
Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?
Ziemka‐Nałęcz, M., Jaworska, J., Sypecka, J., & Zalewska, T. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly073 · Cited by 53
Novel Class of Chalcone Oxime Ethers as Potent Monoamine Oxidase-B and Acetylcholinesterase Inhibitors
Oh, J., Rangarajan, T. M., Chaudhary, R., Singh, R. P., Singh, M., Singh, R. P., Tondo, A. R., Gambacorta, N., Nicolotti, O., Mathew, B., et al. (2020) · Molecules · doi:10.3390/molecules25102356 · Cited by 50
The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer’s disease
Cheng, Y., Chiu, M., Chen, Y., Cheng, T., Lai, Y., & Chen, T. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00658-7 · Cited by 55
Nanotechnology for the diagnosis and treatment of Alzheimer's disease: A bibliometric analysis
Li, L., He, R., Yan, H., Leng, Z., Zhu, S., & Gu, Z. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101654 · Cited by 49
Molecular mechanisms and therapeutic potential of icariin in the treatment of Alzheimer's disease
Zheng, L., Wu, S., Jin, H., Wu, J., Wang, X., Cao, Y., Zhou, Z., Jiang, Y., Li, L., Yang, X., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154890 · Cited by 48
Exploring the therapeutic potential of natural compounds for Alzheimer's disease: Mechanisms of action and pharmacological properties
Liu, J., Li, T., Zhong, G., Pan, Y., Gao, M., Su, S., Liang, Y., Ma, C., Liu, Y., Wang, Q., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115406 · Cited by 54
Current Anti-Amyloid-β Therapy for Alzheimer’s Disease Treatment: From Clinical Research to Nanomedicine
Zhao, Z., Liu, Y., Ruan, S., & Hu, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s444115 · Cited by 49
Cannabinoids in late‐onset Alzheimer's disease
Ahmed, A., van der Marck, M. A., van den Elsen, G., & Rikkert, M. O. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.117 · Cited by 50
Natural β-Dihydroagarofuran-Type Sesquiterpenoids as Cognition-Enhancing and Neuroprotective Agents from Medicinal Plants of the Genus Celastrus
Ning, R., Lei, Y., Liu, S., Wang, H., Zhang, R., Wang, W., Zhu, Y., Zhang, H., & Zhao, W. (2015) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00234 · Cited by 49
An Open-Label, Nonplacebo-Controlled Study on Cistanche tubulosa Glycoside Capsules (Memoregain ® ) for Treating Moderate Alzheimer’s Disease
Guo, Q., Zhou, Y. F., Wang, C.-J., Huang, Y.-M., Lee, Y.-T., Su, M., & Lu, J. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513488907 · Cited by 49
Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal
Kuruva, C. S., & Reddy, P. H. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.10.010 · Cited by 52
Prediction of Anti‐Alzheimer's Activity of Flavonoids Targeting Acetylcholinesterase in silico
Das, S. K., Laskar, M. A., Sarker, S. D., Choudhury, M. D., Choudhury, P. R., Mitra, A., Jamil, S., Lathiff, S. M. A., Abdullah, S. A., Basar, N., et al. (2017) · Phytochemical Analysis · doi:10.1002/pca.2679 · Cited by 49
Upregulated Expression of Heparanase and Heparanase 2 in the Brains of Alzheimer’s Disease
García, B., Martín, C., García‐Suárez, O., Muñiz-Alonso, B., Ordiales, H., Menéndez, S. F., Santos‐Juanes, J., Lorente-Gea, L., Castañón, S., Vicente‐Etxenausia, I., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161298 · Cited by 48
Accumulation of amyloid in cognitive impairment after mild traumatic brain injury
Yang, S.-T., Hsiao, I.-T., Hsieh, C.-J., Chiang, Y.-H., Yen, T.-C., Chiu, W.-T., Lin, K.-J., & Hu, C.-J. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.12.032 · Cited by 53
The Environment Is a Key Factor in Determining the Anti-Amyloid Efficacy of EGCG
Šneideris, T., Sakalauskas, A., Sternke‐Hoffmann, R., Peduzzo, A., Žiaunys, M., Buell, A. K., & Smirnovas, V. (2019) · Biomolecules · doi:10.3390/biom9120855 · Cited by 48
Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by “ Molecular Tweezers” - from the Test Tube to Animal Models
Attar, A., & Bitan, G. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990496 · Cited by 48
Diphenyl ethers from Aspergillus sp. and their anti-Aβ42 aggregation activities
Zhao, H., Wang, G., Tong, X., Chen, G., Huang, Y.-F., Cui, J.-Y., Kong, M.-Z., Guo, L., Zheng, Y., Yao, X., et al. (2014) · Fitoterapia · doi:10.1016/j.fitote.2014.07.007 · Cited by 48
Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease
Padhi, D., & Govindaraju, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00335 · Cited by 47
New idea to promote the clinical applications of stem cells or their extracellular vesicles in central nervous system disorders: Combining with intranasal delivery
Li, Y., Wu, H., Jiang, X., Dong, Y.-F., Zheng, J., & Gao, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.04.001 · Cited by 47
Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer's disease
Šalković‐Petrišić, M., Knezović, A., Barilar, J. O., Smailović, U., Trkulja, V., Riederer, P. F., Amit, T., Mandel, S. A., & Youdim, M. B. H. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.06.026 · Cited by 47
Design, synthesis and biological evaluation of novel 6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo[c]chromen-6-one derivatives as potential cholinesterase inhibitors
Gülcan, H. O., Ünlü, S., Esiringü, İ., Erçeti̇n, T., Şahin, Y., Öz, D., & Sahin, M. F. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.08.016 · Cited by 47
Epigenetic Changes in Neurodegenerative Diseases
Kwon, M. J., Kim, S., Han, M., & Lee, S. B. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.0233 · Cited by 49
Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer’s disease: An autopsy-confirmed study
Morimoto, S., Takao, M., Hatsuta, H., Nishina, Y., Komiya, T., Sengoku, R., Nakano, Y., Uchino, A., Sumikura, H., Saito, Y., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171524 · Cited by 47
Disease-Modifying Effects of M1 Muscarinic Acetylcholine Receptor Activation in an Alzheimer’s Disease Mouse Model
Lebois, E. P., Schroeder, J. P., Esparza, T. J., Bridges, T. M., Lindsley, C. W., Conn, P. J., Brody, D. L., Daniels, J. S., & Levey, A. I. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00278 · Cited by 45
Kaempferol as a potential neuroprotector in Alzheimer's disease
Nejabati, H. R., & Roshangar, L. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14375 · Cited by 47
Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats
Tucci, P., Mhillaj, E., Morgese, M. G., Colaianna, M., Zotti, M., Schiavone, S., Cicerale, M., Trezza, V., Campolongo, P., Cuomo, V., et al. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00332 · Cited by 49
Human genetic variation in VAC14 regulates Salmonella invasion and typhoid fever through modulation of cholesterol
Alvarez, M. I., Glover, L. C., Luo, P. M., Wang, L., Theusch, E., Oehlers, S. H., Walton, E. M., Tram, T. T. B., Kuang, Y., Rotter, J. I., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706070114 · Cited by 44
Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease
Knezović, A., Barilar, J. O., Perhoč, A. B., Bagarić, R., Farkaš, V., Riederer, P. F., & Šalković‐Petrišić, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.027 · Cited by 45
A Computational Systems Pharmacology Approach to Investigate Molecular Mechanisms of Herbal Formula Tian-Ma-Gou-Teng-Yin for Treatment of Alzheimer’s Disease
Wang, T., Wu, Z., Sun, L., Li, W., Liu, G., & Tang, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00668 · Cited by 46
Curcumin-loaded self-nanomicellizing solid dispersion system: part II: in vivo safety and efficacy assessment against behavior deficit in Alzheimer disease
Parikh, A. R., Kathawala, K., Li, J.-T., Chen, C., Shan, Z., Cao, X., Zhou, X., & Garg, S. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0570-0 · Cited by 48
AMPK: Potential Therapeutic Target for Alzheimer's Disease
Yang, L., Jiang, Y., Shi, L., Zhong, D., Li, Y., Li, J., & Jin, R. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190819142746 · Cited by 48
Hydroxyphenylamine phosphonate derivatives: Synthesis, X-ray crystallographic analysis, and evaluation of theirs anti-Alzheimer effects and antioxidant activities
Zaout, S., Chafaa, S., Hellal, A., Boukhemis, O., Khattabi, L., Mérazig, H., Chafai, N., Bensouıcı, C., & Bendjeddou, L. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.129121 · Cited by 46
Design, synthesis, and biological evaluation of novel (4-(1,2,4-oxadiazol-5-yl)phenyl)-2-aminoacetamide derivatives as multifunctional agents for the treatment of Alzheimer's disease
Liu, T., Chen, S., Du, J., Xing, S., Li, R., & Li, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113973 · Cited by 46
Detection of amyloid-beta by Fmoc-KLVFF self-assembled fluorescent nanoparticles for Alzheimer’s disease diagnosis
Liu, D., Fu, D., Zhang, L., & Sun, L. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.09.009 · Cited by 45
Gene Therapy Strategies for Alzheimer's Disease: An Overview
Alves, S., Fol, R., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.017 · Cited by 45
RETRACTED ARTICLE: Quercetin Exhibits α7nAChR/Nrf2/HO-1-Mediated Neuroprotection Against STZ-Induced Mitochondrial Toxicity and Cognitive Impairments in Experimental Rodents
Singh, N. K., & Garabadu, D. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00410-5 · Cited by 45
Retracted
Brain‐targeting drug delivery systems
Liu, P., & Jiang, C. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1818 · Cited by 47
Nodulisporisteriods A and B, the first 3,4-seco-4-methyl-progesteroids from Nodulisporium sp.
Zheng, Q., Chen, G., Kong, M.-Z., Li, G.-Q., Cui, J.-Y., Li, X., Wu, Z., Guo, L., Cen, Y., Zheng, Y., et al. (2013) · Steroids · doi:10.1016/j.steroids.2013.05.007 · Cited by 45
Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer’s disease
Francis, P. T., Parsons, C. G., & Jones, R. W. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.124 · Cited by 47
Discovery of Potent Dual Binding Site Acetylcholinesterase Inhibitors via Homo‐ and Heterodimerization of Coumarin‐Based Moieties
Pisani, L., Catto, M., Palma, A. D., Farina, R., Cellamare, S., & Altomare, C. (2017) · ChemMedChem · doi:10.1002/cmdc.201700282 · Cited by 45
Effect of the Biphenyl Neolignan Honokiol on Aβ42-Induced Toxicity in Caenorhabditis elegans, Aβ42 Fibrillation, Cholinesterase Activity, DPPH Radicals, and Iron(II) Chelation
Kantham, S., Chan, S., McColl, G., Miles, J. A., Veliyath, S. K., Deora, G. S., Dighe, S. N., Khabbazi, S., Parat, M., & Ross, B. P. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00071 · Cited by 45
Sex Differences in the Cognitive and Hippocampal Effects of Streptozotocin in an Animal Model of Sporadic AD
Bao, J., Mahaman, Y. A. R., Liu, R., Wang, J., Zhang, Z., Zhang, B., & Wang, X. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00347 · Cited by 47
Apios americana Medik flowers polysaccharide (AFP-2) attenuates H2O2 induced neurotoxicity in PC12 cells
Chu, Q., Chen, M., Song, D., Li, X., Yang, Y., Zheng, Z., Li, Y., Liu, Y., Yu, L., Zheng, H., et al. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.11.078 · Cited by 45
Isoliquiritigenin Confers Neuroprotection and Alleviates Amyloid-β42-Induced Neuroinflammation in Microglia by Regulating the Nrf2/NF-κB Signaling
Fu, Y., & Jia, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.638772 · Cited by 45
Targeting innate immunity to protect and cure Alzheimer’s disease: opportunities and pitfalls
Cisbani, G., & Rivest, S. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01083-4 · Cited by 44
All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration
Argueti-Ostrovsky, S., Alfahel, L., Kahn, J., & Israelson, A. (2021) · Cells · doi:10.3390/cells10092438 · Cited by 46
Challenges, solutions, and recommendations for Alzheimer's disease combination therapy
Hendrix, J. A., Bateman, R. J., Brashear, H. R., Duggan, C. D., Carrillo, M. C., Bain, L. J., Demattos, R. B., Katz, R. G., Ostrowitzki, S., Siemers, E., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.02.007 · Cited by 44
Astrocytes and Adenosine A2A Receptors: Active Players in Alzheimer’s Disease
Lopes, C. R., Cunha, R. A., & Agostinho, P. M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666710 · Cited by 47
Potential of flavonoids as anti-Alzheimer’s agents: bench to bedside
Kaur, R., Sood, A., Lang, D. K., Bhatia, S., Al‐Harrasi, A., Aleya, L., & Behl, T. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-18165-z · Cited by 45
Advances in microRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders
Long, J. M., & Lahiri, D. K. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.12.043 · Cited by 44
Multi-arm clinical trials with treatment selection: what can be gained and at what price?
Jaki, T. (2015) · Clinical Investigation · doi:10.4155/cli.15.13 · Cited by 43
Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer’s disease
Puli, L., Pomeshchik, Y., Olas, K., Malm, T., Koıstınaho, J., & Tanila, H. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-105 · Cited by 48
Alpha-Linolenic Acid fromPerilla frutescensvar.japonicaOil Protects Aβ-Induced Cognitive Impairment through Regulation of APP Processing and Aβ Degradation
Lee, A. Y., Lee, M. H., Lee, S., & Cho, E. J. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b03941 · Cited by 44
Inhibition of β-Amyloid Aggregation through a Designed β-Hairpin Peptide
Jha, A., Kumar, M. G., Gopi, H. N., & Paknikar, K. M. (2017) · Langmuir · doi:10.1021/acs.langmuir.7b03617 · Cited by 43
Intraventricular infusion of clusterin ameliorated cognition and pathology in Tg6799 model of Alzheimer’s disease
Qi, X.-M., Wang, C., Chu, X., Li, G., & Ma, J. (2018) · BMC Neuroscience · doi:10.1186/s12868-018-0402-7 · Cited by 44
Early intervention attenuates synaptic plasticity impairment and neuroinflammation in 5xFAD mice
Li, K., Wang, X., Jiang, Y., Zhang, X., Liu, Z., Yin, T., & Yang, Z. R. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.007 · Cited by 45
PEGylated-liposomal astaxanthin ameliorates Aβ neurotoxicity and Alzheimer-related phenotypes by scavenging formaldehyde
Gu, Z., Zhao, H., Song, Y., Kou, Y., Yang, W., Li, Y., Li, X., Ding, L., Sun, Z., Lin, J. Y., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.019 · Cited by 46
Amyloid Precursor Proteins Interact with the Heterotrimeric G Protein Go in the Control of Neuronal Migration
Ramaker, J. M., Swanson, T. L., & Copenhaver, P. F. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1146-13.2013 · Cited by 42
Chemical composition, antioxidant, and enzyme inhibitory activities of the essential oils of three Phlomis species as well as their fatty acid compositions
Sarıkürkçü, C., Uren, M. C., Kocak, M. S., Cengiz, M., & Tepe, B. (2016) · Food Science and Biotechnology · doi:10.1007/s10068-016-0120-9 · Cited by 42
Alzheimer's disease markers in the aged sheep (Ovis aries)
Reid, S. J., Mckean, N. E., Henty, K., Portelius, E., Blennow, K., Rudiger, S. R., Bawden, C. S., Handley, R. R., Verma, P. J., Faull, R. L. M., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.020 · Cited by 42
Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine “bio-oxidizable” prodrugs: Synthesis, biological evaluation and structure-activity relationship
Azzouz, R., Peauger, L., Gembus, V., Ţînţaş, M.-L., Santos, J. S. O., Papamicaël, C. A., & Levacher, V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.084 · Cited by 42
Dual effect of chitosan-based nanoparticles on the inhibition of β-amyloid peptide aggregation and disintegration of the preformed fibrils
Jha, A., Ghormade, V., Kolge, H., & Paknikar, K. M. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00162j · Cited by 42
Potassium channels in the neuronal homeostasis and neurodegenerative pathways underlying Alzheimer’s disease: An update
Villa, C., Suphesiz, H., Combi, R., & Akyüz, E. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.111197 · Cited by 42
Probing Fluorinated Motifs onto Dual AChE-MAO B Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Early-ADME Studies
Rullo, M., Cipolloni, M., Catto, M., Colliva, C., Miniero, D. V., Latronico, T., de Candia, M., Benicchi, T., Linusson, A., Giacchè, N., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01784 · Cited by 41
Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer’s Disease?
Natale, G. D., Sabatino, G., Sciacca, M. F. M., Tosto, R., Milardi, D., & Pappalardo, G. (2022) · Molecules · doi:10.3390/molecules27165066 · Cited by 41
Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease
Chiu, M., & Fan, L. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s45143 · Cited by 41
Managing Cognitive Dysfunction through the Continuum of Alzheimerʼs Disease
Delrieu, J., Piau, A., Caillaud, C., Voisin, T., & Vellas, B. J. (2011) · CNS Drugs · doi:10.2165/11539810-000000000-00000 · Cited by 44
The Flavonoid Derivative 2-(4′ Benzyloxyphenyl)-3-hydroxy-chromen-4-one Protects Against Aβ42-Induced Neurodegeneration in Transgenic Drosophila: Insights from In Silico and In Vivo Studies
Singh, S. K., Gaur, R., Kumar, A., Fatima, R., Mishra, L., & Srikrishna, S. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9466-z · Cited by 42

Authors: Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M.
Affiliations: University of Perugia (IT)
University of Eastern Finland (FI)
Karolinska Institutet (SE)
Corresponding author: Winblad, Bengt
ORCID: Mangialasche, Francesca
Solomon, Alina
Winblad, Bengt
Mecocci, Patrizia
Kivipelto, Miia
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2010-07
Volume: 9
Issue: 7
Pages: 702-716
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(10)70119-8
OpenAlex: W2129267808
Cited by: 1,217
References: 161
Citations by year: 2026: 31 · 2025: 47 · 2024: 53 · 2023: 45 · 2022: 91 · 2021: 80 · 2020: 69 · 2019: 77 · 2018: 82 · 2017: 79 · 2016: 78 · 2015: 89 · 2014: 121 · 2013: 97 · 2012: 80
FWCI: 8.96
Type: journal article
Language: en
Update notices: erratum (2011-06-01)
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, drug development, clinical trials, disease-modifying therapy, symptomatic treatment, therapeutic target, pathogenesis, dementia, drug interactions, randomized controlled trials, translational research
MeSH terms: Alzheimer Disease, Clinical Trials as Topic, Humans, Antipsychotic Agents, Drug Design

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alzheimer’s disease: Clinical trials and drug development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks